1 Rheumatological Conditions 1

Janet Cushnaghan and Jackie McDowell

1.1 Introduction 1
1.2 Features of rheumatic conditions 2
- Pain 3
- Stiffness 3
- Swelling 3
- Joint involvement 3
- Function 3
1.3 Epidemiology 4
1.4 Anatomy and physiology of the musculoskeletal system 5
- Muscle 5
- Bone 5
- Cartilage 6
- Synovium 6
- Ligaments and tendons 6
- Tendon sheaths and bursae 6
- Synovial joints 7
- Physiology 7
- Circulation 7
- Lymphatics 7
- Intra-articular pressure 8
- Motion 8
- Innervation 8
- Temperature 8
1.5 Anatomy and physiology of the musculoskeletal system in inflammatory arthritis 9
- Immunopathogenetic mechanisms 9
- Susceptibility 10
- Synovitis 11
1.6 An overview of the rheumatological conditions most commonly encountered in Western Europe 12
   Rheumatoid arthritis 12
   Juvenile idiopathic arthritis 19
   Polymyalgia rheumatica 21
   Inflammatory arthritis associated with spondylitis 22
   Ankylosing spondylitis 22
   Reiter’s syndrome 23
   Psoriatic arthritis 24
   Septic arthritis 26
   Reactive arthritis 28
   Triggering factors 29
   Osteoarthritis 30
   Fibromyalgia syndrome 32
   Connective tissue disease 34
   Systemic lupus erythematosus 34
   Scleroderma (systemic sclerosis) 36
   Inflammatory muscle disease (polymyositis) 41

1.7 The impact of rheumatological conditions on physical, psychological, social and occupational function 45
   Personal impact of arthritis 47
   Financial impact of arthritis 48
   Impact on education 48
   Impact on employment 49
   The role of social support 50
   Impact on family relationships 50
   Depression 52

References 53

2 Drug Therapy 61
Sarah Ryan, Susan Oliver and Ann Brownfield

2.1 Pain 61
   Physiology of pain 62
   Pain receptors 63
   The role of the brain 64
   Physiological effects of acute pain 64

2.2 Pharmacological interventions in rheumatology 65
   Non-opioid analgesia 65
   Compound analgesia 66
   Opioids 66
   Antidepressant drugs 71
   Non-steroidal anti-inflammatory drugs 71
2.3 Disease Modifying Anti-rheumatic Drugs (DMARDs) 81
   Use of DMARDs 81
   Early treatment of RA 81
   Combination therapy 82
   Mode of action and pharmacokinetics of DMARDs 82
   The anti-malarials 83
   Sulfasalazine 85
   D-penicillamine 85
   Myocrisin 86
   Auranofin 87
   Methotrexate 87
   Leflunomide 88
   Azathioprine 88
   Cyclophosphamide 89
   Ciclosporin 89
   Chlorambucil 90
   Phenylbutazone 90
   Dapsone 91
   Minocycline 91
   Mycophenolate Mofetil 91

2.4 Biologic therapies 92
   Introduction 92
   Biologically engineered therapies (biologics) 93
   Classifications — biologic therapies 93
   Mode of action — general 94
   Adverse reactions to biologic therapies 95
   Biologic therapies — treatment options 104
   General issues related to the mode of action — for all anti-TNFα therapies 107
   Side effects that should be considered for all anti-TNFα 108
   Pregnancy and breastfeeding 111
   Immunization 112
   Specific information on anti-TNFα 112
   Biologic therapies — patient issues 119

2.5 The use of steroids in the treatment of rheumatic disease 119
   Glucocorticoids 120
   The use of steroids in rheumatoid arthritis 120
   Corticosteroid sparing agents 121
   Adverse effects of corticosteroids 121
   The use of corticosteroids in other rheumatological conditions 123
   Bone mineral metabolism 124
   Peptic ulceration 125
   Atherosclerosis 125
   Reducing the dose of corticosteroids 125
Pulsed corticosteroids 125
Intramuscular corticosteroids 126
Intra-articular/soft tissue injections of corticosteroids 126

2.6 Disorders of purine metabolism: gout 126
Hyperuricaemia 126

2.7 Nurse prescribing 131
Who should prescribe? 132
Independent prescribing 132
Supplementary prescribing 133
Educational preparation 134
Professional responsibilities 134
Evaluation of prescribing 134

2.8 Self-medication 136
The case for self-medication 136
Advantages of self-medication 137
Stages in the implementation of self-medication 138

2.9 Complementary medicine 139
Diet 140
Massage 141
Aromatherapy 142
Reflexology 142
Acupuncture 142
Herbal medicine 142
Naturopathy 143
Holism 143

2.10 Glucosamine 143
2.11 Capsaicin 145
Conclusion 145

Appendix 2.A What happens next? 145
Appendix 2.B Guidelines for nurses on the use and administration of
intra-articular injections 146
References 148
Appendix 2.C Patient group direction for the administration of
methylprednisolone injection 40 mg/ml by intramuscular
injection 148
Case scenarios 152
References 152

3 The Role of the Nurse in Drug Therapy 163
Sarah Ryan and Margaret Ann Voyce

3.1 What is rheumatology nursing? 163
The nurse—patient relationship 165
3.2 Telephone advice lines 166
3.3 The philosophy of rheumatology nursing 166
3.4 The role of the nurse in drug therapy 168
   Empowerment 168
3.5 The commencement of DMARDs 169
   Patient preparation 169
   Monitoring clinics 170
   Documentation 172
   The use of protocols 172
   Drug monitor clinic protocols 174
3.6 Investigations 177
   Haematological investigations 177
   Biochemical investigations 181
   Assessment of rheumatic disease activity 182
3.7 Urine testing 184
   Appearance 185
   Odour 185
   Measurement of specific gravity 185
   Record keeping 186
3.8 Drugs that require surveillance 187
   Gold (myocrisin) therapy 187
   Auranofin (ridula) therapy in RA 190
   D-penicillamine (distamine) 191
   Sulfasalazine en therapy (salazopyrin) 194
   Methotrexate 196
   Azathioprine (imuran) therapy 199
   Cyclophosphamide (endoxana) therapy 201
   Ciclosporin 203
   Chlorambucil 205
   Phenylbutazone (butacote) 206
   Dapsone 207
   Minocycline (minocin) 208
   Leflunomide 208
   Mycophenolate Mofetil 211
3.9 Vaccination 212
3.10 Pregnancy 212
   Contraception 214
3.11 The role of the community team in drug therapy 214
   Minimizing confusion 215
3.12 Community drug monitoring 216
   Documentation 217
   GPs’ concerns relating to practice-based monitoring 218
   Patients’ experiences of drug monitoring 218
3.13 Community clinics 218
3.14 General practice 219
3.15 Evaluation of community clinics 219
   Potential problems with consultant-based community
   clinics 220
3.16 Nurse-led community clinics 220
3.17 New ways of utilizing outpatient appointments 222
3.18 Drug therapy and osteoporosis 222
   Classification of osteoporosis 222
   Risk factors for osteoporosis fracture 223
   Investigations for osteoporosis 224
3.19 Hormone replacement therapy (HRT) 224
3.20 Pain management 225
3.21 Drugs to reduce fracture risk 225
   Bisphosphonates 225
   Etidronate 225
   Alendronate Sodium (fosamax) 225
3.22 Other drug treatments 226
   Calcitonin 226
   Calcium 226
   Vitamin D 227
   Calcitriol 227
   Formation stimulating agents 227
   Strontium ranelate (protelos) 227
3.23 Prevention (lifestyle strategies) 228
   Diet 228
   Smoking 228
   Alcohol 228
   Exercise 228
   Falls 228
Conclusion 229
Appendix 3.A 229
Appendix 3.B 232
References 235

4 Patient Education and Adherence with Drug Therapy 243
   Jackie Hill

4.1 Definitions of patient education 243
4.2 Useful theories and models 244
   Learned helplessness theory 245
   Stress and coping theory 245
   Health belief model 246
   Self-efficacy theory 247
4.3 Purpose of patient education 250
4.4 Limitations of patient education 251
4.5 Role of the nurse in patient education 252
    Patient education and some fundamental aspects of nursing 252
    Patient education and therapeutic nursing 252
    Reciprocity 252
    Professional closeness 253
4.6 Planning a patient education programme 254
    The learning environment 254
    Demographic considerations 255
    Disease duration 255
    Age range 255
    Diagnosis 256
    Mixed educational ability 256
    The type of programme 256
4.7 Individual patient education 257
    Preferences of drug therapy 257
    Assess the patients’ knowledge of drugs 258
    Establishing shared goals 259
    Preferred method of information transfer 259
    Contracting 260
    The activity to be accomplished 260
    The plan of action 260
    Checking that the contract is realistic 260
4.8 Teaching in groups 261
4.9 Opportunity education 262
4.10 The arthritis self-management programme 262
4.11 What to teach 263
    Teaching about drug therapy 264
    What to include 265
    Risks and adverse effects 266
4.12 Teaching aids 267
    Videos and CDs 270
    Audiocassettes 270
    Computer programs 270
4.13 The optimum timing of patient education 271
    Readiness for change 271